High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
about
Treatment of relapsed and refractory multiple myelomaFrom clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyA prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaIntegrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.Proteasome inhibitors in the treatment of multiple myelomaRetrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.The use of novel agents in the treatment of relapsed and refractory multiple myelomaBortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.Successful treatment of primary advanced gastric plasmacytoma using a combination of surgical resection and chemotherapy with bortezomib: A case report.Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.Current multiple myeloma treatment strategies with novel agents: a European perspectiveDevelopment of target-specific treatments in multiple myeloma.Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Proteasome inhibitors in multiple myeloma: 10 years later.Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.Emerging pathways as individualized therapeutic target of multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.Bortezomib-induced peripheral neurotoxicity: an update.Current treatment landscape for relapsed and/or refractory multiple myeloma.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.An inhibitor of ubiquitin conjugation and aggresome formation.Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.The proteasome and proteasome inhibitors in multiple myeloma.Triplet vs. doublet drug regimens for managing multiple myeloma.United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.
P2860
Q26749180-5F652B1B-415C-4A15-A9AC-47CD3C5B1A1EQ26862828-0D7BC0E6-3754-48A0-8B32-02DB074BF8E5Q28082910-AA29E329-BDCB-4ACA-AC6C-6CEB90AA6025Q33405134-E842969A-13B5-4BA9-8404-843286E49EAFQ33408056-91CC4E6B-A307-4D08-B85F-90A7E8D6FE5CQ33409681-6E225B79-934E-4574-BF41-DA812FB3A77EQ33411708-94106D8C-E40A-4207-8B4F-911BCDB256A7Q33415759-184BCD4E-CBFB-40C1-AE32-07FF61158CE9Q33416105-B8283B0D-D01C-4A6E-B01B-A8AEF16C0AD4Q33418300-327628B5-0077-481D-BBBA-8507352B2C8BQ33442798-4831AB64-64E9-42AD-AECD-90A2257DB5FBQ34269238-82D70916-6E40-4CDF-9CC0-CD044ABFA042Q34611676-C967EEEC-D73C-45D0-9435-BC971A63E54EQ34798095-86796F6F-47E0-4D1A-A202-83D9D8ECCF50Q35097319-7942B684-9E66-450E-A34A-479A468D5974Q35836881-0586FC6D-87B7-4DBA-BD8F-D10EB41FD030Q37228026-6EFA00BF-C510-49DD-BCBD-0773442B7247Q37246012-AA109464-2074-4FDF-9E16-73105A6B19E6Q37275721-7E7D35AE-E8DF-465C-8118-6C4B7569A0CFQ37507513-07CFC384-0C9C-4B62-8528-3684FB320435Q37677935-C4AA9BC5-CB04-47BC-B8E5-4A9721DB9B45Q37771370-D4EE5002-6070-4686-B88A-2BEAF9B71740Q37829230-02599659-C1DA-43BD-8670-AF264CA668C4Q37949201-235FBC5E-584E-40B1-A4BE-74D10B8A7275Q38014395-80E493C9-7190-4A57-8551-334C7B734CD8Q38020248-015E51B0-CE8F-4DF3-8DE1-19F806064FFDQ38112176-B6B676E0-0E46-406A-A659-D119C314F408Q38187476-3B898556-2C27-4AA4-934D-48BE6A0738E4Q38234733-DD787931-FF70-437C-BCC3-9D3211C85654Q38271032-F579845D-3A5A-4DEE-A7D9-EFB9FEC1BA45Q38757067-ECF5EB8A-E8E6-4596-9BEC-1662AC7DF3BBQ40047253-A94E6C82-67C4-41D2-B0BE-9C3D940D5713Q40454277-E5C1128A-1DC7-48F5-BD0B-0428A9D764D2Q40956670-25590F5F-4C37-4E1C-930A-DB9C61171B31Q42357207-DDAFAFA1-51DA-46EC-8D81-9AADCBEB359AQ47339695-5314E163-3B98-4C2F-ABCC-23935E13B833Q47770089-689425B8-7F66-481E-B7AD-110CA78858F1Q52841629-D18A5193-4213-4C2C-8145-BA5409DB51B2
P2860
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
High response rate to bortezom ...... se 3b expanded access program.
@ast
High response rate to bortezom ...... se 3b expanded access program.
@en
type
label
High response rate to bortezom ...... se 3b expanded access program.
@ast
High response rate to bortezom ...... se 3b expanded access program.
@en
prefLabel
High response rate to bortezom ...... se 3b expanded access program.
@ast
High response rate to bortezom ...... se 3b expanded access program.
@en
P2093
P1476
High response rate to bortezom ...... se 3b expanded access program.
@en
P2093
A Keith Stewart
Alessandro Corso
Andrew R Belch
Angelo Maiolino
H Miles Prince
Joseph R Mikhael
Maria Nambo Lucio
Maria Teresa Petrucci
Mieczyslaw Komarnicki
P304
P356
10.1111/J.1365-2141.2008.07409.X
P407
P577
2008-11-19T00:00:00Z